US3947573A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Opthalmic solution
Assignee: Alcon Vision LLC
•
Filing: 1974-10-18
•
Granted: 1976-03-30
•
Expires: 1994-10-18
Abstract
Abstract An ophthalmic solution is provided for treatment of "dry eye", providing lubricating and cushioning effects for traumatized eyes, including trauma caused by the wearing of hard or gel-type contact lenses, and as a carrier for ophthalmic medicaments. The solution is an aqueous solution of polyethylene oxide, optionally polyethylene glycol, and other optional ingredients.
Inventors
- 👤 Billy F. Rankin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:18
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; C; C08; C08L; C08L71/00; C08L71/02
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
118 words
An opthalmic solution consisting essentially of an aqueous solution of an ethylene oxide polymer, having a molecular weight of at least about 100,000, in an amount of from about 0.05 to 2.0 weight percent sufficient to provide a viscosity of from about 0 to 30,000 cps, from about 100 to about 5,000 weight percent, based on the ethylene oxide polymer, of a lower polyalkylene glycol, having a molecular weight from about 400 to about 6,000 and from .5 to 10 percent polyvinyl pyrrolidone based on the weight of the overall solution, said composition further including a therapeutically effective amount up to about 500 weight percent, based on the weight of the ethylene oxide polymer of an opthalmic medicament.
Claim 2
Dependent Claim
118 words
An opthalmic solution consisting essentially of an aqueous solution of an ethylene oxide polymer, having a molecular weight of at least about 100,000, in an amount of from about 0.05 to 2.0 weight percent sufficient to provide a viscosity of from about 0 to 30,000 cps, from about 100 to about 5,000 weight percent, based on the ethylene oxide polymer, of a lower polyalkylene glycol, having a molecular weight from about 400 to about 6,000 and from .5 to 10 percent polyvinyl pyrrolidone based on the weight of the overall solution, said composition further including a therapeutically effective amount up to about 500 weight percent, based on the weight of the ethylene oxide polymer of an opthalmic medicament.
Claim 3
Dependent Claim
19 words
The composition of claim 1 wherein said ethylene oxide polymer has a molecular weight of about 3,000,000 to 5,000,000.
Claim 4
Dependent Claim
17 words
The composition of claim 1 wherein said ethylene oxide polymer has a molecular weight of about 4,000,000.
Claim 5
Dependent Claim
12 words
The composition of claim 1 wherein said polyalkylene glycol is polyethylene glycol.
Claim 6
Dependent Claim
19 words
The composition of claim 4 wherein said polyethylene glycol has a molecular weight of from about 400 to 6,000.
Claim 7
Dependent Claim
16 words
The composition of claim 4 wherein said polyethylene glycol has a molecular weight of about 4,000.
Claim 8
Dependent Claim
20 words
The composition of claim 1 wherein said aqueous solution further comprises an effective amount of an eye compatible pH buffer.
Claim 9
Dependent Claim
11 words
The composition of Claim 7 wherein said buffer is boric acid.
Claim 10
Dependent Claim
16 words
The composition of claim 7 wherein said buffer is a combination of mono-sodium and di-sodium phosphates.
Claim 11
Dependent Claim
34 words
The composition of claim 1 wherein said aqueous solution further comprises a mechanical buffer selected from the group consisting of methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropyl methyl cellulose, and mixtures thereof.
Claim 12
Dependent Claim
23 words
The composition of claim 1 wherein said aqueous solution further comprises up to about 1 percent by weight of an eye compatible biocide.
Claim 13
Dependent Claim
24 words
The composition of claim 1 wherein said aqueous solution further comprises up to about 0.5 percent by weight of an eye compatible non-ionic surfactant.
Claim 14
Dependent Claim
12 words
The composition of claim 1, wherein the opthalmic medicament is pilocarpine HCl.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-03-30 | 1979-09-29 | 1980-03-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-03-30 | 1983-09-29 | 1984-03-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-03-30 | 1987-09-29 | 1988-03-30 | $7700.00 | Window Closed / Lapsed |